73 related articles for article (PubMed ID: 22289920)
41. The molecular basis of synergism between carboplatin and ABT-737 therapy targeting ovarian carcinomas.
Jain HV; Meyer-Hermann M
Cancer Res; 2011 Feb; 71(3):705-15. PubMed ID: 21169413
[TBL] [Abstract][Full Text] [Related]
42. Diminished sensitivity of chronic lymphocytic leukemia cells to ABT-737 and ABT-263 due to albumin binding in blood.
Vogler M; Furdas SD; Jung M; Kuwana T; Dyer MJ; Cohen GM
Clin Cancer Res; 2010 Aug; 16(16):4217-25. PubMed ID: 20601444
[TBL] [Abstract][Full Text] [Related]
43. mTOR signaling orchestrates the expression of cytoprotective factors during cellular senescence.
Yosef R; Krizhanovsky V
Oncotarget; 2016 Aug; 7(31):48859. PubMed ID: 27447572
[No Abstract] [Full Text] [Related]
44. Resistance to ABT-199 induced by microenvironmental signals in chronic lymphocytic leukemia can be counteracted by CD20 antibodies or kinase inhibitors.
Thijssen R; Slinger E; Weller K; Geest CR; Beaumont T; van Oers MH; Kater AP; Eldering E
Haematologica; 2015 Aug; 100(8):e302-6. PubMed ID: 25957396
[No Abstract] [Full Text] [Related]
45. Emerging drugs for chronic lymphocytic leukaemia.
Yee KW; O'Brien SM
Expert Opin Emerg Drugs; 2006 Mar; 11(1):167-89. PubMed ID: 16503834
[TBL] [Abstract][Full Text] [Related]
46. ABT-199 for chronic lymphocytic leukemia.
Seymour J
Clin Adv Hematol Oncol; 2014 Oct; 12(10):698-700. PubMed ID: 25658896
[No Abstract] [Full Text] [Related]
47. Impaired immune surveillance accelerates accumulation of senescent cells and aging.
Ovadya Y; Landsberger T; Leins H; Vadai E; Gal H; Biran A; Yosef R; Sagiv A; Agrawal A; Shapira A; Windheim J; Tsoory M; Schirmbeck R; Amit I; Geiger H; Krizhanovsky V
Nat Commun; 2018 Dec; 9(1):5435. PubMed ID: 30575733
[TBL] [Abstract][Full Text] [Related]
48. Aberrant telomere structure is characteristic of resistant chronic lymphocytic leukaemia cells.
Brugat T; Gault N; Baccelli I; Maës J; Roborel de Climens A; Nguyen-Khac F; Davi F; Merle-Béral H; Gilson E; Goodhardt M; Delic J
Leukemia; 2010 Jan; 24(1):246-51. PubMed ID: 19847201
[No Abstract] [Full Text] [Related]
49. [Not Available].
Li DQ; Kumar R
Hepatology; 2013 Mar; 57(3):1287-8. PubMed ID: 22815144
[No Abstract] [Full Text] [Related]
50. Targeting chromatin remodelers to treat hepatocellular carcinoma.
Vinciguerra M
Hepatology; 2013 Mar; 57(3):1287. PubMed ID: 22745026
[No Abstract] [Full Text] [Related]
51. [New hope for the cancer patient?].
Holzgrabe U; Bennack E
Pharm Unserer Zeit; 2006; 35(2):101. PubMed ID: 16583562
[No Abstract] [Full Text] [Related]
52. The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia.
Secchiero P; di Iasio MG; Melloni E; Voltan R; Celeghini C; Tiribelli M; Dal Bo M; Gattei V; Zauli G
Leukemia; 2010 Feb; 24(2):480-3. PubMed ID: 19847196
[No Abstract] [Full Text] [Related]
53. Pair-bonding through epigenetics.
Gundersen B
Nat Neurosci; 2013 Jul; 16(7):779. PubMed ID: 23799469
[No Abstract] [Full Text] [Related]
54. Behaviour: epigenetically bonded.
Flight MH
Nat Rev Neurosci; 2013 Jul; 14(7):457. PubMed ID: 23756635
[No Abstract] [Full Text] [Related]
55. Subtotal splenectomy for the treatment of chronic lymphocytic leukemia.
Petroianu A
Blood Cancer J; 2015 Mar; 5(3):e289. PubMed ID: 25768403
[No Abstract] [Full Text] [Related]
56. Metabolism meets apoptosis in AML.
Timofeeva N; Gandhi V
Leuk Lymphoma; 2021 Mar; 62(3):514-516. PubMed ID: 33356786
[No Abstract] [Full Text] [Related]
57. Histone deacetylase inhibitors are unable to synergize with ABT-737 in killing primary chronic lymphocytic leukaemia cells in vitro.
Ralli R; Banks KM; Wiegmans AP; Carney D; Seymour JF; Johnstone RW; Alsop AE
Leukemia; 2012 Jun; 26(6):1433-5. PubMed ID: 22289920
[No Abstract] [Full Text] [Related]
58. Promise of combining a Bcl-2 family inhibitor with bortezomib or SAHA for adult T-cell leukemia/lymphoma.
Kunami N; Katsuya H; Nogami R; Ishitsuka K; Tamura K
Anticancer Res; 2014 Oct; 34(10):5287-94. PubMed ID: 25275021
[TBL] [Abstract][Full Text] [Related]
59. ABT-737, proving to be a great tool even before it is proven in the clinic.
Vaux DL
Cell Death Differ; 2008 May; 15(5):807-8. PubMed ID: 18408737
[No Abstract] [Full Text] [Related]
60. N-(4-hydroxyphenyl)retinamide promotes apoptosis of resting and proliferating B-cell chronic lymphocytic leukemia cells and potentiates fludarabine and ABT-737 cytotoxicity.
Bruno S; Ghiotto F; Tenca C; Mazzarello AN; Bono M; Luzzi P; Casciaro S; Recchia A; Decensi A; Morabito F; Fais F
Leukemia; 2012 Oct; 26(10):2260-8. PubMed ID: 22475870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
